2010 RWISO Journal - Roth Williams International Society of ...

29. Zardeneta G, Milam SB, Lee T, Schmitz JP. Detection and preliminary
characterization of matrix metalloproteinase activity in
temporomandibular joint lavage fluid. Int J Oral Maxillofac Surg.
1998;27(5):397-403.
30. Kubota E, Imamura H, Kubota T, Shibata T, Murakami K. Interleukin
1 beta and stromelysin (MMP3) activity of synovial fluid as
possible markers of osteoarthritis in the temporomandibular joint. J
Oral Maxillofac Surg. 1997;55(1):20-27.
31. Kubota E, Kubota T, Matsumoto J, Shibata T, Murakami KI. Synovial
fluid cytokines and proteinases as markers of temporomandibular
joint disease. J Oral Maxillofac Surg. 1998;56(2):192-198.
32. Kanyama M, Kuboki T, Kojima S, et al. Matrix metalloproteinases
and tissue inhibitors of metalloproteinases in synovial fluids of
patients with temporomandibular joint osteoarthritis. J Orofac Pain.
2000;14(1):20-30.
33. Marchetti C, Cornaglia I, Casasco A, Bernasconi G, Baciliero U,
Stetler-Stevenson WG. Immunolocalization of gelatinase-A (matrix
metalloproteinase-2) in damaged human temporomandibular joint
discs. Arch Oral Biol. 1999;44(4):297-304.
34. Kapila S, Wang W, Uston K. Matrix metalloproteinase induction
by relaxin causes cartilage matrix degradation in target synovial joints.
Ann N Y Acad Sci. 2009;1160:322-328.
35. Shinoda C, Takaku S. Interleukin-1 beta, interleukin-6, and tissue
inhibitor of metalloproteinase-1 in the synovial fluid of the temporomandibular
joint with respect to cartilage destruction. Oral Dis.
2000;6(6):383-390.
36. Kanyama M, Kuboki T, Kojima S, et al. Matrix metalloproteinases
and tissue inhibitors of metalloproteinases in synovial fluids of
patients with temporomandibular joint osteoarthritis. J Orofac Pain.
2000;14(1):20-30.
37. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T.
Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial
mechanisms. Adv Dent Res. 1998;(12):12-26.
38. Golub LM, Lee HM, Greenwald RA, et al. A matrix metalloproteinase
inhibitor reduces bone-type collagen degradation fragments and
specific collagenases in gingival crevicular fluid during adult periodontitis.
Inflamm Res. 1997;(46):310-319.
39. Smith GN Jr, Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition
of matrix metalloproteinase activity by doxycycline: relationship
to structure of the enzyme. Arthritis Rheum. 1999;42(6):1140-1146.
40. Schlondorff D, Satriano J. Interactions with calmodulin: potential
mechanism for some inhibitory actions of tetracyclines and calcium
channel blockers. Biochem Pharmacol. 1985;34(18):3391-3393.
41. Webster GF, Toso SM, Hegemann L. Inhibition of a model of in
vitro granuloma formation by tetracyclines and ciprofloxacin: involvement
of protein kinase C. Arch Dermatol. 1994;130(6):748-752.
42. Kirkwood K, Martin T, Andreadis ST, Kim YJ. Chemically modified
tetracyclines selectively inhibit IL-6 expression in osteoblasts by decreasing
mRNA stability. Biochem Pharmacol. 2003;66(9):1809-1819.
43. Arner EC, Hughes CE, Decicco CP, Caterson B, Tortorella MD.
Cytokine-induced cartilage proteoglycan degradation is mediated by
aggrecanase. Osteoarthritis Cartilage. 1998;6(3):214-228.
44. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action
of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad
Sci U S A. 1996;93(24):14014-14019.
45. Borderie D, Hernvann A, Hilliquin P, Lemarchal H, Kahan
A, Ekindjian OG. Tetracyclines inhibit nitrosothiol production
by cytokine-stimulated osteoarthritic synovial cells. Inflamm Res.
2001;50(8):409-414.
46. Shlopov BV, Stuart JM, Gumanovskaya ML, Hasty KA. Regulation
of cartilage collagenase by doxycycline. J Rheumatol. 2001;28(4):835-
842.
47. Holmes SG, Still K, Buttle DJ, Bishop NJ, Grabowski PS. Chemically
modified tetracyclines act through multiple mechanisms directly
on osteoclast precursors. Bone. 2004;35(2):471-478.
48. Bettany JT, Peet NM, Wolowacz RG, Skerry TM, Grabowski PS.
Tetracyclines induce apoptosis in osteoclasts. Bone. 2000;27(1):75-80.
49. Bettany JT, Wolowacz RG. Tetracycline derivatives induce apoptosis
selectively in cultured monocytes and macrophages but not in
mesenchymal cells. Adv Dent Res. 1998;12(2):136-143.
50. Ramamurthy N, Greenwald R, Moak S, et al. CMT/Tenidap
treatment inhibits temporomandibular joint destruction in adjuvant
arthritic rats. Ann N Y Acad Sci. 1994; (732):427-430.
51. Yu LP Jr, Burr DB, Brandt KD, O’Connor BL, Rubinow A, Albrecht
M. Effects of oral doxycycline administration on histomorphometry
and dynamics of subchondral bone in a canine model of osteoarthritis.
J Rheumatol. 1996;(23):137-142.
52. Yu LP Jr, Smith GN Jr, Brandt KD, Myers SL, O’Connor BL, Brandt
DA. Reduction of the severity of canine osteoarthritis by prophylactic
treatment with oral doxycycline. Arthritis Rheum. 1992;(35):1150-
1159.
53. Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline
treatment be used more extensively for rheumatoid arthritis?
Metaanalysis demonstrates clinical benefit with reduction in disease
activity. J Rheumatol. 2003;30(10):2112-2122.
54. Sreekanth VR, Handa R, Wali JP, Aggarwal P, Dwivedi SN. Doxycycline
in the treatment of rheumatoid arthritis--a pilot study. J Assoc
Physicians India. 2000;(48):804-807.
55. Israel HA, Ramamurthy NS, Greenwald R, Golub L. The potential
role of doxycycline in the treatment of osteoarthritis of the temporomandibular
joint. Adv Dent Res. 1998; (12):51-55.
56. Golub LM, Sorsa T, Lee HM, et al. Doxycycline inhibits neutrophil
(PMN)-type matrix metalloproteinases in human adult periodontitis
gingiva. J Clin Periodontol. 1995; 22(2):100-109.
57. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration
of doxycycline in patients with small asymptomatic abdominal aortic
aneurysms: report of a prospective (phase II) multicenter study. J Vasc
Surg. 2002;36(1):1-12.
RWISO Journal | September 2010
43